{"protocolSection":{"identificationModule":{"nctId":"NCT00821821","orgStudyIdInfo":{"id":"MCI-186-E04"},"organization":{"fullName":"Mitsubishi Tanabe Pharma Corporation","class":"INDUSTRY"},"briefTitle":"Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke","officialTitle":"A Phase IIa, Multi-centre, Randomised, Double-blind, Placebo Controlled, Clinical Study Investigating the Safety, Tolerability and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke"},"statusModule":{"statusVerifiedDate":"2014-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-02"},"primaryCompletionDateStruct":{"date":"2010-11","type":"ACTUAL"},"completionDateStruct":{"date":"2010-11","type":"ACTUAL"},"studyFirstSubmitDate":"2009-01-13","studyFirstSubmitQcDate":"2009-01-13","studyFirstPostDateStruct":{"date":"2009-01-14","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-01-05","resultsFirstSubmitQcDate":"2014-04-07","resultsFirstPostDateStruct":{"date":"2014-05-12","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-04-07","lastUpdatePostDateStruct":{"date":"2014-05-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Mitsubishi Tanabe Pharma Corporation","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The objectives of this study are to assess the safety, tolerability and local tolerance, and to investigate the plasma levels and terminal elimination half life of MCI-186, and to review the routine clinical and neurological assessments data of MCI-186 in subjects with acute ischemic stroke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke (AIS)"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":36,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"MCI-186","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-186"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"MCI-186","description":"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion\n\nCohort 2: Edaravone: circa 2000 mg / 72-hour infusion","armGroupLabels":["MCI-186"],"otherNames":["Edaravone"]},{"type":"DRUG","name":"Placebo","description":"Cohort1:circa 1000mg / 72-hour infusion matching placebo\n\nCohort2:circa 2000mg / 72-hour infusion matching placebo","armGroupLabels":["Placebo Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants That Experienced Adverse Events","description":"Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency.","timeFrame":"87days"}],"secondaryOutcomes":[{"measure":"Plasma MCI-186 Pharmacokinetics","description":"The geometric mean values of MCI-186 plasma concentration at the end of the infusion (at 72h) in cohorts 1 and 2 were determined.","timeFrame":"72 hours"},{"measure":"mRS, NIHSS, Barthel Index","timeFrame":"throughout study"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Full functional independence prior to the present stroke (as evidenced by a pre-morbid modified Rankin Scale score of 0-2\n* Clinical diagnosis of acute stroke with CT scan ruling out intracranial hemorrhage\n* Onset of symptoms within 1-24 hours of commencement of infusion of study drug\n* Measurable deficit on NIHSS (as evidenced by a score of 3-15)\n* Full consciousness (i.e. the score for NIHSS item 1a=0)\n* Written valid informed consent is obtained from the subject or his/her next of kin or legal representative if the subject is fully conscious (i.e. the score for NIHSS item 1a = 0) but unable to read and/or sign the ICF, in accordance with National legislation and local IRB requirements\n\nExclusion Criteria:\n\n* Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition\n* Subjects with severe illness with life expectancy less than 6 months\n* Body weight in excess of 120 kg\n* Subjects who have received rTPA or other thrombolytics (e.g. urokinase, streptokinase, reteplase, tenecteplase) within the previous 24 hours\n* Likelihood of forbidden concomitant therapy such as vascular surgery, coronary artery bypass graft (CABG), valve replacement, or carotid endarterectomy (CEA)\n* Evidence of cerebral herniation\n* Subjects with confounding neurological diseases such as dementia\n* Subjects with CADASIL, Moya Moya, or carotid dissection\n* Subjects who have experienced a stroke within the previous 3 months (Note: subjects who have recently experienced a TIA, but whose premorbid mRS prior to their stroke is 0-2, will be allowed to enter the study)\n* Evidence from admission imaging tests of infarction involving \\>1/3 of MCA territory, or entire ACA territory involvement, or internal carotid artery (ICA) occlusions without coexisting separate occlusion of the middle cerebral artery (because of the difficulty distinguishing between chronic and acute ICA lesions in such subjects)\n* Pathology other than cerebral infarction on any admission imaging tests (e.g. ICH or SAH, AV malformation, cerebral aneurysm, or cerebral neoplasm)\n* Current or previous known excessive alcohol use or dependence\n* Current known illicit drug use or dependence\n* Participation in a previous clinical study within 30 days\n* Subjects unlikely to be able and willing to attend all study follow-up visits\n* Any other conditions which in the opinion of the investigator deem the subject ineligible for inclusion\n* Females who are pregnant or intend to become pregnant or subjects (male and female) who do not agree to use effective contraception for 3 months after end of treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Professor","affiliation":"Information at Mitsubishi Pharma Europe","role":"STUDY_CHAIR"}],"locations":[{"facility":"Helsinki University Central Hospital","city":"Helsinki","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Erasmus Medical Center","city":"Rotterdam","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Newcastle upon Tyne Hospitals NHS Foundation Trust","city":"Newcastle","country":"United Kingdom","geoPoint":{"lat":54.97328,"lon":-1.61396}}]},"referencesModule":{"references":[{"pmid":"24135530","type":"RESULT","citation":"Kaste M, Murayama S, Ford GA, Dippel DW, Walters MR, Tatlisumak T; MCI-186 study group. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen. Cerebrovasc Dis. 2013;36(3):196-204. doi: 10.1159/000353680. Epub 2013 Oct 12. Erratum In: Cerebrovasc Dis. 2013;36(5-6):461."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"MCI-186 Cohort1","description":"Edaravone: circa 1000 mg / 72-hour infusion"},{"id":"FG001","title":"MCI-186 Cohort2","description":"Edaravone: circa 2000 mg / 72-hour infusion"},{"id":"FG002","title":"Placebo Group","description":"Cohort1:circa 1000mg / 72-hour infusion matching placebo\n\nCohort2:circa 2000mg / 72-hour infusion matching placebo"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"13"},{"groupId":"FG002","numSubjects":"11"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"MCI-186 Cohort1","description":"Edaravone: circa 1000 mg / 72-hour infusion"},{"id":"BG001","title":"MCI-186 Cohort2","description":"Edaravone: circa 2000 mg / 72-hour infusion"},{"id":"BG002","title":"Placebo Group","description":"Cohort1:circa 1000mg / 72-hour infusion matching placebo\n\nCohort2:circa 2000mg / 72-hour infusion matching placebo"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"36"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"16"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"20"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"9"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"27"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants That Experienced Adverse Events","description":"Additional Outcome Measures are included in Tables for Serious Adverse Events and Other Adverse Events to report their numbers and frequency.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"87days","groups":[{"id":"OG000","title":"MCI-186 Cohort1","description":"Edaravone: circa 1000 mg / 72-hour infusion"},{"id":"OG001","title":"MCI-186 Cohort2","description":"Edaravone: circa 2000 mg / 72-hour infusion"},{"id":"OG002","title":"Placebo Group","description":"Cohort1:circa 1000mg / 72-hour infusion matching placebo\n\nCohort2:circa 2000mg / 72-hour infusion matching placebo"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"11"}]}],"classes":[{"title":"Deaths","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Serious Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}]}]},{"title":"Other Adverse Events","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}]}]}]},{"type":"SECONDARY","title":"Plasma MCI-186 Pharmacokinetics","description":"The geometric mean values of MCI-186 plasma concentration at the end of the infusion (at 72h) in cohorts 1 and 2 were determined.","populationDescription":"The subjects with reliable measured values for plasma concentration were selected for pharmacokinetic analysis: 5 subjects in MCI-186 Cohort 1 and 11 subjects in MCI-186 Cohort 2.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ng / ml","timeFrame":"72 hours","groups":[{"id":"OG000","title":"MCI-186 Cohort1","description":"Edaravone:circa 1000mg / 72-hour infusion"},{"id":"OG001","title":"MCI-186 Cohort2","description":"Edaravone:circa 2000mg / 72-hour infusion"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"11"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"391","spread":"24.21","lowerLimit":"45.81","upperLimit":"3338"},{"groupId":"OG001","value":"1595","spread":"51.57","lowerLimit":"958.3","upperLimit":"2655"}]}]}]},{"type":"SECONDARY","title":"mRS, NIHSS, Barthel Index","reportingStatus":"NOT_POSTED","timeFrame":"throughout study"}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"87 days","eventGroups":[{"id":"EG000","title":"MCI-186 Cohort1","description":"Edaravone: circa 1000mg / 72-hour infusion","seriousNumAffected":0,"seriousNumAtRisk":12,"otherNumAffected":12,"otherNumAtRisk":12},{"id":"EG001","title":"MCI-186 Cohort2","description":"Edaravone: circa 2000mg / 72-hour infusion","seriousNumAffected":2,"seriousNumAtRisk":13,"otherNumAffected":10,"otherNumAtRisk":13},{"id":"EG002","title":"Placebo Group","description":"Cohort1:circa 1000mg / 72-hour infusion matching placebo\n\nCohort2:circa 2000mg / 72-hour infusion matching placebo","seriousNumAffected":1,"seriousNumAtRisk":11,"otherNumAffected":10,"otherNumAtRisk":11}],"seriousEvents":[{"term":"Gout","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Ischaemic Stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]}],"otherEvents":[{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Vision Blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Abdominal Pain Lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Gastrooesophageal Reflux Disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Mouth Ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Infusion Site Phlebitis","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Vessel Puncture Site Haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Eczema Infected","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Groin Abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Infusion Site Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Blood Alkaline Phosphatase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Blood Creatine Phosphokinase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Blood Glucose Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Blood Uric Acid Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"C-Reactive Protein Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Gamma-Glutamyltransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Hepatic Enzyme Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Liver Function Test Abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Diabetes Mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":2,"numAtRisk":11}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Muscle Spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Cerebrovascular Accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":12},{"groupId":"EG001","numAffected":4,"numAtRisk":13},{"groupId":"EG002","numAffected":4,"numAtRisk":11}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Simple Partial Seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Speech Disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Transient Ischaemic Attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Urethral Haemorrhage","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Urinary Incontinence","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pleural Fibrosis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Pulmonary Oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Erythema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":12},{"groupId":"EG001","numAffected":0,"numAtRisk":13},{"groupId":"EG002","numAffected":1,"numAtRisk":11}]},{"term":"Stasis Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":12},{"groupId":"EG001","numAffected":2,"numAtRisk":13},{"groupId":"EG002","numAffected":4,"numAtRisk":11}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 11.1","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":12},{"groupId":"EG001","numAffected":1,"numAtRisk":13},{"groupId":"EG002","numAffected":0,"numAtRisk":11}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Clinical Trials, Information Desk","organization":"Mitsubishi Tanabe Pharma Corporation","email":"cti-inq-ml@ml.mt-pharma.co.jp"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077553","term":"Edaravone"}],"ancestors":[{"id":"D000016166","term":"Free Radical Scavengers"},{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018696","term":"Neuroprotective Agents"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M1831","name":"Edaravone","asFound":"Lay","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}